Literature DB >> 11425920

Energy hypometabolism in posterior cingulate cortex of Alzheimer's patients: superficial laminar cytochrome oxidase associated with disease duration.

J Valla1, J D Berndt, F Gonzalez-Lima.   

Abstract

Among brain regions affected in Alzheimer's disease (AD), the posterior cingulate shows the earliest and largest decrement in energy metabolism. Positron emission tomography (PET) studies have shown that these decrements appear before the onset of memory deficits or other symptoms in persons at genetic risk for AD. This study compares in vivo imaging results and in situ postmortem analyses by examining the posterior cingulate (area 23) in 15 AD patients and 13 age-matched nondemented controls using quantitative cytochrome oxidase histochemistry as an intracellular measure of oxidative energy metabolic capacity. Each of the six layers of the posterior cingulate demonstrated a decline in cytochrome oxidase activity in AD relative to controls, whereas adjacent motor cortex showed no significant differences. This decrement did not appear to be mainly secondary to nonspecific decrement in mitochondrial enzymes, oxidative stress, cell loss, or histopathology. The cytochrome oxidase decrement was most severe in the superficial layer I (-39%), which demonstrated a correlation to disease duration. Covariance analyses suggest that superficial laminas undergo a functional uncoupling from the deeper layers of posterior cingulate cortex in AD, whereas no such effects are found in motor cortex or controls. These findings expand on previous results from PET studies by illuminating the layer-specific cytochrome oxidase contributions to energy hypometabolism. The findings suggest a decrement of cytochrome oxidase in posterior cingulate cortex, with progressive reduction within the superficial laminas linked to disease duration. Such decrement could contribute to some of the behavioral symptoms displayed by AD patients. This decrement appeared greater in women.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11425920      PMCID: PMC6762373     

Source DB:  PubMed          Journal:  J Neurosci        ISSN: 0270-6474            Impact factor:   6.167


  44 in total

1.  The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer's disease.

Authors:  S S Mirra; A Heyman; D McKeel; S M Sumi; B J Crain; L M Brownlee; F S Vogel; J P Hughes; G van Belle; L Berg
Journal:  Neurology       Date:  1991-04       Impact factor: 9.910

Review 2.  Evolution of neuronal changes in the course of Alzheimer's disease.

Authors:  H Braak; E Braak
Journal:  J Neural Transm Suppl       Date:  1998

3.  Age-related differences in neural activity during memory encoding and retrieval: a positron emission tomography study.

Authors:  R Cabeza; C L Grady; L Nyberg; A R McIntosh; E Tulving; S Kapur; J M Jennings; S Houle; F I Craik
Journal:  J Neurosci       Date:  1997-01-01       Impact factor: 6.167

4.  Quantitative cytochemistry of cytochrome oxidase and cellular morphometry of the human inferior colliculus in control and Alzheimer's patients.

Authors:  F Gonzalez-Lima; J Valla; S Matos-Collazo
Journal:  Brain Res       Date:  1997-03-28       Impact factor: 3.252

5.  Distribution of cerebral degeneration in Alzheimer's disease. A clinico-pathological study.

Authors:  A Brun; L Gustafson
Journal:  Arch Psychiatr Nervenkr (1970)       Date:  1976-12-31

6.  Posterior cingulate cortex in Alzheimer's disease.

Authors:  S Minoshima; N L Foster; D E Kuhl
Journal:  Lancet       Date:  1994-09-24       Impact factor: 79.321

7.  Longitudinal evaluation of early Alzheimer's disease using brain perfusion SPECT.

Authors:  D Kogure; H Matsuda; T Ohnishi; T Asada; M Uno; T Kunihiro; S Nakano; M Takasaki
Journal:  J Nucl Med       Date:  2000-07       Impact factor: 10.057

8.  Regional brain effects of sodium azide treatment on cytochrome oxidase activity: a quantitative histochemical study.

Authors:  A Cada; F Gonzalez-Lima; G M Rose; M C Bennett
Journal:  Metab Brain Dis       Date:  1995-12       Impact factor: 3.584

9.  Neuronal activity and early neurofibrillary tangles in Alzheimer's disease.

Authors:  K Hatanpää; D R Brady; J Stoll; S I Rapoport; K Chandrasekaran
Journal:  Ann Neurol       Date:  1996-09       Impact factor: 10.422

10.  Preclinical prediction of Alzheimer's disease using SPECT.

Authors:  K A Johnson; K Jones; B L Holman; J A Becker; P A Spiers; A Satlin; M S Albert
Journal:  Neurology       Date:  1998-06       Impact factor: 9.910

View more
  94 in total

Review 1.  Antioxidants in the canine model of human aging.

Authors:  Amy L S Dowling; Elizabeth Head
Journal:  Biochim Biophys Acta       Date:  2011-10-08

2.  Age- and transgene-related changes in regional cerebral metabolism in PSAPP mice.

Authors:  Jon Valla; Lonnie Schneider; Eric M Reiman
Journal:  Brain Res       Date:  2006-08-30       Impact factor: 3.252

3.  Accumulation of amyloid precursor protein in the mitochondrial import channels of human Alzheimer's disease brain is associated with mitochondrial dysfunction.

Authors:  Latha Devi; Badanavalu M Prabhu; Domenico F Galati; Narayan G Avadhani; Hindupur K Anandatheerthavarada
Journal:  J Neurosci       Date:  2006-08-30       Impact factor: 6.167

4.  Anterior thalamic lesions produce chronic and profuse transcriptional de-regulation in retrosplenial cortex: A model of retrosplenial hypoactivity and covert pathology.

Authors:  G L Poirier; K L Shires; D Sugden; E Amin; K L Thomas; D A Carter; J P Aggleton
Journal:  Thalamus Relat Syst       Date:  2008-03

Review 5.  Amyloid-beta-induced mitochondrial dysfunction.

Authors:  John Xi Chen; Shi Du Yan
Journal:  J Alzheimers Dis       Date:  2007-09       Impact factor: 4.472

6.  Alzheimer's disease is associated with reduced expression of energy metabolism genes in posterior cingulate neurons.

Authors:  Winnie S Liang; Eric M Reiman; Jon Valla; Travis Dunckley; Thomas G Beach; Andrew Grover; Tracey L Niedzielko; Lonnie E Schneider; Diego Mastroeni; Richard Caselli; Walter Kukull; John C Morris; Christine M Hulette; Donald Schmechel; Joseph Rogers; Dietrich A Stephan
Journal:  Proc Natl Acad Sci U S A       Date:  2008-03-10       Impact factor: 11.205

Review 7.  Creatine and its potential therapeutic value for targeting cellular energy impairment in neurodegenerative diseases.

Authors:  Peter J Adhihetty; M Flint Beal
Journal:  Neuromolecular Med       Date:  2008-11-13       Impact factor: 3.843

Review 8.  Multivariate meta-analyses of mitochondrial complex I and IV in major depressive disorder, bipolar disorder, schizophrenia, Alzheimer disease, and Parkinson disease.

Authors:  L Holper; D Ben-Shachar; J J Mann
Journal:  Neuropsychopharmacology       Date:  2018-05-16       Impact factor: 7.853

9.  Dose-dependent effects of ladostigil on microglial activation and cognition in aged rats.

Authors:  Marta Weinstock; Corina Bejar; Donna Schorer-Apelbaum; Rony Panarsky; Lisandro Luques; Shai Shoham
Journal:  J Neuroimmune Pharmacol       Date:  2013-01-17       Impact factor: 4.147

10.  Alzheimer's brains harbor somatic mtDNA control-region mutations that suppress mitochondrial transcription and replication.

Authors:  Pinar E Coskun; M Flint Beal; Douglas C Wallace
Journal:  Proc Natl Acad Sci U S A       Date:  2004-07-09       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.